Dr Kazuhiko Uchida is a Director of Institute for Biomedical Research, MCBI, Inc. Education and degrees: 1983: Nara Medical University (M.D.) 1983–1987: Graduate School of Medical Sciences, Nara Medical University (M.D., Ph.D.) Work experience: 1985–1989: Research Staff, National Cancer Center Research Institute, Tokyo 1989–2022: Faculty of Medicine, University of Tsukuba 2004–present: MCBI, Inc. Research Interests: Dementia, Clinical research, Biomarker Membership: The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). Uchida K. Waste Clearance in the Brain and Neuroinflammation: A Novel Perspective on Biomarker and Drug Target Discovery in Alzheimer’s Disease. Cells,11:919; 2022 Nakamura S, Uchida K, et al. A Novel Cognitive Function Scale Using Functional Near-Infrared Spectroscopy for Evaluating Cognitive Dysfunction. J Alzheimers Dis. 81:1579–1588, 2021. Ide M, Uchida K, et al. Excess hydrogen sulfide and polysulfides production underlies a schizophrenia pathophysiology. EMBO Mol Med, 11:e10695, 2019. Shan L, Uchida K, et al. Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment. Alzheimers Dement (Amst), 11:85–97, 2019. Uchida K, et al. Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline. Alzheimers Dement (Amst) 1:270–280, 2015.